首页> 美国卫生研究院文献>Frontiers in Chemistry >Targeting Dengue Virus NS-3 Helicase by Ligand based Pharmacophore Modeling and Structure based Virtual Screening
【2h】

Targeting Dengue Virus NS-3 Helicase by Ligand based Pharmacophore Modeling and Structure based Virtual Screening

机译:基于配体的药效团建模和基于结构的虚拟筛选靶向登革热病毒NS-3解旋酶

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dengue fever is an emerging public health concern, with several million viral infections occur annually, for which no effective therapy currently exist. Non-structural protein 3 (NS-3) Helicase encoded by the dengue virus (DENV) is considered as a potential drug target to design new and effective drugs against dengue. Helicase is involved in unwinding of dengue RNA. This study was conducted to design new NS-3 Helicase inhibitor by in silico ligand- and structure based approaches. Initially ligand-based pharmacophore model was generated that was used to screen a set of 1201474 compounds collected from ZINC Database. The compounds matched with the pharmacophore model were docked into the active site of NS-3 helicase. Based on docking scores and binding interactions, 25 compounds are suggested to be potential inhibitors of NS3 Helicase. The pharmacokinetic properties of these hits were predicted. The selected hits revealed acceptable ADMET properties. This study identified potential inhibitors of NS-3 Helicase in silico, and can be helpful in the treatment of Dengue.
机译:登革热是一种新兴的公共卫生问题,每年有数百万的病毒感染发生,目前尚无有效的治疗方法。登革热病毒(DENV)编码的非结构蛋白3(NS-3)解旋酶被认为是设计针对登革热的新型有效药物的潜在药物靶标。解旋酶与展开登革热RNA有关。进行了这项研究,以基于计算机配体和结构的方法设计新的NS-3解旋酶抑制剂。最初生成了基于配体的药效团模型,该模型用于筛选从ZINC数据库收集的一组1201​​474化合物。将与药效团模型匹配的化合物停靠在NS-3解旋酶的活性位点中。根据对接分数和结合相互作用,建议有25种化合物可能是NS3解旋酶的抑制剂。这些命中的药代动力学特性是可以预测的。所选的匹配显示出可接受的ADMET属性。这项研究在计算机上确定了潜在的NS-3解旋酶抑制剂,并可能有助于登革热的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号